查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138385

全球葡萄膜炎治疗市场-2022-2029

Global Uveitis Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

主要驱动因素是葡萄膜炎发病率的上升、赠款和奖学金的存在以及研发活动的增加。

不断增加的研发活动正在推动全球市场的增长。

根据临床试验，例如，越来越多的治疗眼部炎症的临床试验正在全球范围内进行。例如，由鲁汶大学 (Universitaire Ziekenhuizen Leuven) 赞助的一项研究，旨在评估阿巴西普作为一种免疫抑制疗法治疗鸟击性葡萄膜炎的疗效和安全性，预计将于 2023 年 1 月 1 日在华盛顿大学医学院完成五项试验目前正在积极解决葡萄膜炎的干预措施，包括一项託法替尼治疗炎症性眼病的研究，由 .由 Vastra Gotaland 地区赞助的研究，重点是预计将于 2022 年 12 月结束的葡萄膜炎患者的疏水性和亲水性人工晶状体的结果，由天津医科大学张小米赞助 这包括一项 4 期试验，测试英夫利昔单抗在临床上可用于治疗的假设难治性小儿葡萄膜炎患者，预计2022年12月完成。此外，已经招募了 35 项临床试验，表明全球市场的未来增长。

高成本、潜在的药物副作用和严格的法规将阻碍全球葡萄膜炎治疗市场的增长。

但是，预计高价格、与药物相关的副作用以及缺乏对眼病的了解将抑制市场增长。预计流泪和炎症等药物副作用也会阻碍市场增长。

行业分析

全球葡萄膜炎治疗市场报告根据波特五力、研发、流行病学、监管、价格和管道分析等各种行业因素对市场进行了深入分析。

COVID-19 影响分析

在大流行期间，为遏制 COVID-19 的传播实施了许多限制措施，这对全球市场产生了负面影响，扰乱了供需链并减少了葡萄膜炎治疗药物的销售。此外，社会化法规使得定期进行眼科检查变得困难，导致大多数葡萄膜炎患者未被发现，对全球葡萄膜炎药物市场产生负面影响。

全球葡萄膜炎治疗市场报告将提供对大约 40 多个市场数据表、45 多个数字和 200 页（大约）的访问。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 不断发展的研发
      • 葡萄膜炎患者增加
      • 市场策略
    • 限制因素
      • 高成本
      • 药物的副作用
      • 严格的监管机构
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 流行病学分析
  • 研发
  • 管道分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型

  • 肾上腺皮质类固醇
  • 免疫抑製剂
  • 单克隆抗体
  • 抗生素
  • 其他

第 8 章按疾病类型

  • 前葡萄膜炎
  • 后葡萄膜炎
  • 中间葡萄膜炎
  • 全葡萄膜炎

第 9 章原因

  • 非传染性
  • 传染性

第 10 章按销售渠道

  • 医院药房
  • 零售药房
  • 在线药店

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 13 章公司简介

  • Bausch & Lomb Incorporated
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Santen Pharmaceutical Co., Ltd
  • AbbVie Inc.
  • Eyegate Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals
  • Eyepoint Pharmaceuticals Inc.
  • Alimera Sciences, Inc.
  • Clearside Biomedical, Inc.
  • Aldeyra Therapeutics, Inc

第14章 DataM

简介目录
Product Code: DMPH2170

Market Overview

Uveitis Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Uveitis is an inflammation of the middle layer of an eye (uvea), also known as the uveal tract. Auto-immune disorders, injuries, inflammatory disorders, infections, and surgeries are common causes of uveitis. Common symptoms of uveitis include eye pain, eye floaters, blurred vision, increased sensitivity to light and redness of the eye.

Market Dynamics

The major driving forces are the rising incidence of uveitis, the presence of grants and fellowships, growing research and development activities.

The growing research and development activities are fueling the global market growth.

An increasing number of clinical trials for eye inflammation treatment are being conducted globally, for instance, according to the clinical trials. Gov currently, five different clinical trials are actively working on intervention for Uveitis, such as a study to estimate the efficiency and safety of Abatacept for Birdshot uveitis as an immunosuppressive treatment sponsored by Universitaire Ziekenhuizen Leuven and estimated completion on January 1, 2023, a study on Tofacitinib for the treatment of inflammatory eye disease sponsored by Washington University School of Medicine, a study focused on the outcome with the hydrophobic and hydrophilic intraocular lens in patients with and without uveitis sponsored by Vastra Gotaland Region and estimated completion on December 2022 and a phase 4 study to test the hypothesis that infliximab is clinically useful for patients with refractory childhood uveitis sponsored by Xiaomin Zhang, Tianjin Medical University and predicted completion by December 2022. Furthermore, 35 more clinical studies are recruiting, indicating the global market's future growth.

The high cost, chances of drug side effects and stringent regulations will be the demoting reasons for the global Uveitis Treatment market growth.

However, the high prices, the side effects associated with the medications, and the lack of knowledge regarding eye disorders are expected to restrain the market growth. Also, the side effects of medications like watery eyes and irritation will likely hamper the market growth.

Industry analysis.

The global uveitis treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, and pipeline analysis.

COVID-19 Impact Analysis

During the pandemic, the global market was negatively affected as many restrictions were imposed to limit the COVID-19 spread, which led to the disruption of the supply and demand chain, reducing the sales of Uveitis Treatment. Furthermore, the socializing restriction made it difficult to get regular eye checkups, leaving most uveitis patients undetected, negatively impacting the global uveitis treatment market.

Segment Analysis

Corticosteroids are presumed to be prevailing throughout the forecast period (2022-2029)

The corticosteroid segment is expected to grow at a high rate since it is considered the mainstay treatment for patients with non-infectious uveitis. Corticosteroid drugs are very useful in minimizing inflammation. The FDA approved several corticosteroid eye drops available on the market. Ophthalmologists generally recommend eye drops, oral medications, or injections of corticosteroids. Corticosteroid implant is also increasingly gaining traction for people with chronic eye inflammation disorders. For instance, Retisert of Bausch+Lomb is the US's first FDA-approved surgical corticosteroid implant for treating non-infectious posterior uveitis. Many novel clinical trials are developing for uveitis. For instance, a phase 2 trial for the efficiency and safety of the Interleukin-17A inhibitor Izokibep (ABY-035) for treating a non-infectious intermediate, posterior or pan-uveitis (LINNAEA) sponsored by ACELYRIN Inc. and estimated to be complete by November 2022 and clinical study on Abatacept in Patients With Birdshot HLA A29 Uveitis: a phase II prospective 0pen label interventional proof-of-concept study sponsored by Universitaire Ziekenhuizen Leuven and estimated to be completed by January 1, 2023.

Geographical Analysis

The North American region is overshadowing the global uveitis treatment market.

North America dominated the Uveitis Treatment market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase of approximately 15 cases per 100,000 population annually or some 38,000 new cases annually. It is a significant cause of blindness, accounting for 10-15% of all blindness in the United States, costing approximately $242 million annually. Furthermore, the NIH states that Uveitis is very common in the geriatric population and as the American geriatric population is growing at a high rate is contributing to its dominance over the market. For instance, as per the estimation from the U.S. Census Bureau, more than 56 million American adults aged 65 and older in the United States account for about 16.9% of the nation's population. By 2030, when the last person from the boomer generation ages into older adulthood, it is projected that there will be more than 73.1 million older adults.

Competitive Landscape

Competitive Landscape

The major players operating in the global uveitis treatment market are Bausch & Lomb Incorporated, Santen Pharmaceutical Co., Ltd, AbbVie Inc., Eyegate Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences, Inc., Clearside Biomedical, Inc., and Aldeyra Therapeutics, Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the uveitis treatment market globally. For instance, on May 8, 2020, AbbVie Inc. acquired Allergan plc. Also, on JUNE 2, 2022, Bausch + Lomb announced Launched Biotrue Hydration Plus, a multi-purpose solution.

Bausch + Lomb

Overview

Bausch + Lomb is a leading eye health products manufacturing company headquartered in Canada and was founded in 1853. It is among the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. Bausch + Lomb, on May 6, 2022, became a publicly traded company in 2021; around 21,000 employees were working for Bausch + Lomb.

Product Portfolio

Bausch + Lomb Company's uveitis product portfolio has XIPERE, VISUDYNE and RETISERT.

The global uveitis treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development
      • 4.1.1.2. Growing Cases of Uveitis
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost
      • 4.1.2.2. Drug Side Effects
      • 4.1.2.3. Stringent Regulatory Bodies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Corticosteroids
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Immunosuppressant
  • 7.4. Monoclonal Antibodies
  • 7.5. Antibiotics
  • 7.6. Others

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 8.1.2. Market Attractiveness Index, By Disease Type Segment
  • 8.2. Anterior Uveitis
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Posterior Uveitis
  • 8.4. Intermediate Uveitis
  • 8.5. Panuveitis

9. By Cause

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
    • 9.1.2. Market Attractiveness Index, By Cause Segment
  • 9.2. Non-Infectious
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious

10. By Distribution Channels

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
    • 10.1.2. Market Attractiveness Index, By Distribution Channels Segment
  • 10.2. Hospital Pharmacies
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Bausch & Lomb Incorporated
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Santen Pharmaceutical Co., Ltd
  • 13.3. AbbVie Inc.
  • 13.4. Eyegate Pharmaceuticals, Inc.
  • 13.5. Regeneron Pharmaceuticals
  • 13.6. Eyepoint Pharmaceuticals Inc.
  • 13.7. Alimera Sciences, Inc.
  • 13.8. Clearside Biomedical, Inc.
  • 13.9. Aldeyra Therapeutics, Inc

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact